DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
57 hedge funds and large institutions have $36.2M invested in DMK Pharmaceuticals Corporation Common Stock in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 6 closing their positions.
184% more capital invested
Capital invested by funds: $12.7M → $36.2M (+$23.5M)
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
12% more funds holding
Funds holding: 51 → 57 (+6)
77% less call options, than puts
Call options by funds: $561K | Put options by funds: $2.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$11.6M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.88M |
| 3 |
BlackRock
New York
|
+$2.02M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.82M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$292K |
| 2 |
Walleye Trading
New York
|
-$159K |
| 3 |
LCM
Leisure Capital Management
Costa Mesa,
California
|
-$123K |
| 4 |
VF
Virtu Financial
New York
|
-$77K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWM
51
Geneos Wealth Management
Englewood,
Colorado
| $5K | +$1.66K | +7 | +41% |
|
|
WAM
52
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $4K | – | – | – |
|
|
SPIA
53
Steward Partners Investment Advisory
New York
| $3K | -$5.92K | -25 | -66% |
|
|
S
54
SignatureFD
Atlanta,
Georgia
| $3K | – | – | – |
|
|
VCM
55
Versant Capital Management
Phoenix,
Arizona
| $2K | -$10.9K | -46 | -79% |
|
|
FDCDDQ
56
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.75K | -$2.13K | -9 | -56% |
|
|
VF
57
Virtu Financial
New York
| – | -$77K | -342 | Closed |
|
|
TSS
58
Two Sigma Securities
New York
| – | -$45K | -199 | Closed |
|
59
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$37K | -164 | Closed |
|
60
D.E. Shaw & Co
New York
| – | -$34K | -152 | Closed |
|
61
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$5K | -23 | Closed |
|
|
FIA
62
FNY Investment Advisers
New York
| – | -$2K | -11 | Closed |
|
DMK Hedge Fund Activity: Q3 2018 in Review
57 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2018, worth a combined $36.2M — up 184% from $12.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new DMK positions and 6 closed out — a net gain of 6 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was First Manhattan, opening a new position worth an estimated $11.6M. The largest seller was Bank of Montreal, cutting an estimated $292K.
- 57 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2018, up from 51 in Q2 2018.
- Funds reported $36.2M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2018, up 184% quarter-over-quarter.
- 12 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2018 and 6 closed out, a net change of +6 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2018 was First Manhattan, an estimated $11.6M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2018 was Bank of Montreal, an estimated $292K sold.
Based on aggregated 13F filings for Q3 2018.